Boston An independent LDT provider

Immunovia, Inc. achieves Clinical Laboratory Licensure from Rhode Island Dept of Health making IMMray™ PanCan-d test available in 46 US states

May 17, 2022

LUND, SWEDEN – The Rhode Island Department of Health has granted Immunovia, Inc., the US subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), Clinical Laboratory licensure, allowing physicians in Rhode Island to order the IMMray™ PanCan-d test for their patients.

“Receiving licensure in Rhode Island now allows us to offer IMMray™ PanCan-d in 46 states. We expect additional state licensures to follow, as we work to make IMMray™ PanCan-d accessible to patients across the United States who are at risk for pancreatic cancer,” says Jeff Borcherding, Chief Executive Officer of Immunovia, Inc., the US subsidiary of Immunovia AB.

For more information, please contact:
Philipp Mathieu
Acting CEO and President
Email: philipp.mathieu@immunovia.com
 

Tobias Bülow
Senior Director Investor Relations and Corporate Communications
Email: tobias.bulow@immunovia.com
Tel: +46 736 36 35 74

The information was submitted for publication on May 17, 2022, at 08:30 am CET.